English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B

van Bömmel, F., van Bömmel, A., Krauel, A., Wat, C., Pavlovic, V., Yang, L., et al. (2018). Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. The Journal of Infectious Diseases, 218(7), 1066-1074. doi:10.1093/infdis/jiy270.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0003-6EC5-4 Version Permalink: http://hdl.handle.net/21.11116/0000-0003-6EC6-3
Genre: Journal Article

Files

show Files
hide Files
:
van Bömmel.pdf (Publisher version), 343KB
Name:
van Bömmel.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© The Author(s) 2018
License:
-

Locators

show
hide
Description:
-

Creators

show
hide
 Creators:
van Bömmel, Florian, Author
van Bömmel, Alena1, Author              
Krauel, Alexander, Author
Wat, Cynthia, Author
Pavlovic, Vedran, Author
Yang, Lei, Author
Deichsel, Danilo, Author
Berg, Thomas, Author
Bohm, Stephan, Author
Affiliations:
1Dept. of Computational Molecular Biology (Head: Martin Vingron), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1433547              

Content

show
hide
Free keywords: PegIFN, stopping rules, CHB, biomarkers, HBV RNA, life cycle
 Abstract: Background: Hepatitis B virus (HBV) RNA is a novel serum biomarker that has the potential to predict treatment response in patients with chronic hepatitis B. We explored whether HBV RNA serum levels can predict hepatitis B e antigen (HBeAg) seroconversion in patients treated with peginterferon alfa-2a. Methods: Serum samples from HBeAg-positive patients previously treated with peginterferon alfa-2a in 2 large randomized controlled trials were retrospectively analyzed. HBV RNA levels were measured using a real-time polymerase chain reaction assay. Ability of individual biomarkers to predict HBeAg seroconversion at 24 weeks posttreatment was evaluated using receiver operating characteristics (ROC) analyses. Results: The study included 131 subjects (70% male, 96% Asians, 35% HBV genotypes B, and 61% C), 76 treated with peginterferon alfa-2a alone and 55 in combination with lamivudine. Median HBV RNA levels were significantly lower, at all timepoints, in patients achieving HBeAg seroconversion. Levels of HBV RNA at treatment weeks 12 and 24 showed good ability to predict HBeAg seroconversion (area under ROC scores >0.75, P < .001). A HBV RNA cutoff of >5.5 log10 copies/mL identified 30% of nonresponders at week 12 (negative predictive value >90%). Conclusion: Serum HBV RNA is an early predictor of HBeAg seroconversion in patients treated with peginterferon alfa-2a. Clinical Trials Registration: NCT01705704.

Details

show
hide
Language(s): eng - English
 Dates: 2018-05-082018-05-082018-08-24
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1093/infdis/jiy270
ISSN: 1537-6613 (Electronic)0022-1899 (Print)
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: The Journal of Infectious Diseases
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Oxford University Press
Pages: - Volume / Issue: 218 (7) Sequence Number: - Start / End Page: 1066 - 1074 Identifier: -